Vitiligo and Cosmetic Surgery: Why White Patches Can Appear in a New Scar, How to Tell Stable Vitiligo From Active Disease, What Ruxolitinib Cream, Light Therapy, and Grafting Actually Do, and Which Lasers, Tattoos, and Garments to Approach With Care

The patch usually appears somewhere unremarkable. A pale spot at the corner of the mouth, around a knuckle, on the shin, near the eye. It has a crisp edge, it does not itch or flake, and on lighter skin it may go unnoticed until a summer tan makes the surrounding skin darker and the spot stands out like a hole in a photograph. On deeper skin tones it is visible from the first week. Over months it may stay the same, grow slowly, or be joined by others, often in mirror image on the other side of the body.

That is vitiligo, and it affects somewhere between half a percent and two percent of people worldwide, across every skin tone and in men and women about equally. It is not contagious, it is not caused by anything the patient did, and it is not dangerous to physical health in the way most medical conditions discussed on this site are. For many people, though, it is a heavy cosmetic and emotional burden, and the combination of visible skin change and a desire to look a certain way brings a fair number of them into dermatology and plastic surgery offices.

Vitiligo matters to cosmetic surgery for a reason that is easy to miss: in many patients, injury to the skin can cause new white patches to form exactly where the injury was. A facelift incision, a laser treatment, a tattooed eyebrow, a tight waistband, or the seam of a post-operative garment can all, in the wrong patient at the wrong time, leave behind a white line or patch that was not there before. Whether that risk is high, low, or close to zero depends mostly on one question: is the disease stable or active right now?

This piece explains what vitiligo is and how it is distinguished from other causes of white skin, what stability means and why it decides almost everything, how skin trauma triggers new patches and what that means for incisions, lasers, tattoos, and garments, what medical treatment can achieve, and how surgical repigmentation works. It is general information, not a diagnosis. A new white patch on the skin should be examined by a dermatologist before anyone treats it as cosmetic.

What vitiligo is, and how it differs from other white patches

The short answer: vitiligo is an autoimmune disease in which T cells attack and destroy melanocytes, the pigment-producing cells in the skin and hair, and it is diagnosed by its milky, sharply bordered patches, which glow bright under a Wood's lamp in a way that most other causes of light skin do not.

Skin color comes from melanin, made by melanocytes that sit along the base of the epidermis and in hair follicles. In vitiligo, those cells are targeted by the immune system. Research over the past fifteen years has mapped the mechanism in some detail: stressed melanocytes release signals that attract cytotoxic T cells, and a cytokine called interferon gamma drives a loop through the JAK and STAT signaling pathway that recruits still more immune cells into the skin. That pathway is the reason a new class of drugs, the JAK inhibitors, now works for vitiligo, a point the treatment section returns to.

Vitiligo is classified in two main forms:

• Nonsegmental vitiligo is by far the more common. Patches tend to be symmetrical, appearing on both hands, both sides of the face, both knees, and they favor areas around the eyes and mouth, the fingers and wrists, the elbows and knees, the genitals, and places that see friction. It often runs an unpredictable course, with periods of spread and periods of quiet that can last years.
• Segmental vitiligo affects one side of the body in a band or segment, often starts in childhood, spreads quickly for a year or two, and then usually stops. It is less often linked to other autoimmune disease and, for reasons that will matter later, tends to respond well to surgical treatment once it has settled.

Because vitiligo is autoimmune, it travels with other autoimmune conditions. Thyroid disease is the most important; studies commonly find thyroid autoimmunity in a substantial minority of adults with nonsegmental vitiligo, often reported in the range of one in ten to one in five. The American Academy of Dermatology and most vitiligo guidelines suggest at least checking thyroid function. Anyone with vitiligo who is planning surgery should know whether their thyroid has been tested, which is part of the wider picture discussed in the piece on cosmetic surgery with autoimmune disease and, for eyelid surgery in particular, the piece on thyroid eye disease and eyelid surgery.

Not every pale patch is vitiligo, and the difference matters because the treatments are different. The common lookalikes include:

• Post-inflammatory hypopigmentation, lightening left behind after a rash, a burn, a peel, or a laser treatment. The skin is lighter but not chalk white, and it usually recovers over months. It is a recognized risk of resurfacing, discussed in the pieces on ablative and non-ablative laser resurfacing and the deep phenol peel.
• Pityriasis alba, faint, slightly scaly pale patches on the cheeks of children and young adults, often with dry or eczema-prone skin.
• Tinea versicolor, a yeast overgrowth that leaves fine, scaly spots on the chest and back and is treated with antifungals.
• Idiopathic guttate hypomelanosis, small, confetti-like white spots on the shins and forearms of people with years of sun exposure.
• Mature stretch marks and scars, which are pale because the skin structure changed, not because pigment cells were attacked. The distinction comes up in the piece on old stretch marks that won't fade.

A dermatologist will usually make the diagnosis by looking, aided by a Wood's lamp, a handheld ultraviolet light under which vitiligo patches show a bright, blue-white fluorescence with sharp borders. Biopsy is rarely needed. White hairs inside a patch (leukotrichia) are a useful clue, and, as later sections explain, a meaningful predictor of how the patch will respond to treatment.

Stable or active: the question that decides almost everything

The short answer: before any elective procedure that injures the skin, the most important fact about a patient's vitiligo is whether it is currently stable, which most surgical guidelines define as no new patches, no enlarging patches, and no new white areas at sites of injury for roughly the past 12 months.

Vitiligo has no blood test that says whether it is active. Stability is judged clinically, from history and examination, and the signs of activity are specific enough that patients can often answer the question themselves:

• New patches appearing in the past several months.
• Existing patches getting larger, which is easiest to judge from dated photographs taken in the same light.
• Confetti-like depigmentation, clusters of tiny white dots at the edge of a patch or in new areas, a recognized sign of rapid spread.
• Trichrome vitiligo, a blurry intermediate zone of partially lightened skin between the white patch and normal skin, suggesting the border is moving.
• Inflammatory borders, a faintly red or raised edge, which is uncommon but signals active immune attack.
• Koebner phenomenon, meaning new white patches at sites of recent cuts, scratches, burns, or friction, which is both a sign of activity and the central concern for anyone having surgery.

Dermatologists use scoring tools to capture this. One of the older ones, the Vitiligo Disease Activity score, simply asks when the patient last saw new or enlarging lesions: within six weeks, three months, six months, a year, or not for more than a year. The details vary by scoring system, but the point is the same. A patient whose last change was two years ago is in a very different position from one whose patches grew last month.

The 12-month threshold comes mainly from the surgical treatment of vitiligo itself, where grafting into an active patch tends to fail and grafting near one can create new patches at the donor site. Many experts apply the same logic to elective cosmetic procedures. No society has issued a binding rule on how long someone with vitiligo must wait before a tummy tuck or a fractional laser, and much of the evidence here is observational, but a year of quiet disease is the yardstick most dermatologists and plastic surgeons use when they think about the question at all. For active disease, the usual advice is to treat the vitiligo first, wait for it to settle, and then revisit the cosmetic plan.

Segmental vitiligo deserves a separate note. Because it typically stops spreading after its first year or two and is less prone to the Koebner phenomenon than the nonsegmental form, a patient with long-stable segmental disease is often treated more like someone without vitiligo, at least for procedures away from the affected segment.

"

The question is not whether a patient has vitiligo. It is whether the vitiligo is doing anything right now, and nobody can answer that from a single look at the skin on the day of the consultation.

"

This is also why photographs matter. Patients with vitiligo often have years of phone photos that show exactly how their patches have changed, and those photos are better evidence of stability than a description from memory. A surgeon who asks to see them is doing the job properly; one who does not ask has probably not thought about the issue.

The Koebner problem: incisions, lasers, tattoos, and garments

The short answer: in a substantial share of people with vitiligo, especially those with active nonsegmental disease, injury to the skin can cause a new white patch to form at the site of injury within weeks, which means an incision line, a laser treatment area, a tattooed brow, or a band of garment friction can all become new vitiligo.

The Koebner phenomenon (also called isomorphic response) is named after the German dermatologist Heinrich Koebner, who described it in psoriasis in the 1870s. In vitiligo, estimates of how many patients show it vary widely between studies, from about a fifth to more than half depending on how carefully it is looked for, and it is consistently more common in active disease. The mechanism is not fully understood, but the working explanation is that injury stresses melanocytes and releases danger signals that attract the same immune attack that drives vitiligo elsewhere.

Some practical consequences for cosmetic procedures:

• Surgical incisions. A Koebner response along a scar looks like a white line, usually wider than the incision itself, appearing a few weeks to a few months after surgery. On a deeper skin tone this can be far more visible than the scar it surrounds. It is the main reason a surgeon should know about vitiligo before choosing where to place incisions, and it adds a layer to the general advice in the piece on scar care after plastic surgery.
• Lasers, peels, and microneedling. Any treatment that injures the epidermis carries some Koebner risk in active disease. Ablative resurfacing is the most aggressive, but even fractional and non-ablative treatments create controlled injury. In stable disease, interestingly, researchers have deliberately combined fractional carbon dioxide laser with phototherapy or topical drugs to improve repigmentation in resistant patches, so injury is not always harmful, but that is a supervised treatment of the vitiligo, not a cosmetic laser in a patient whose disease is in motion. The general tradeoffs of these treatments appear in the pieces on lasers versus chemical peels and PRP and microneedling.
• Pigment lasers. Lasers designed to lighten sun spots and melasma target melanin. In someone with vitiligo, especially on the face, that is a treatment worth discussing twice, because a lightened spot next to a white patch can be hard to interpret and active disease may respond badly to the injury. The general field is covered in the pieces on lasers for sun spots and pigmentation and what actually works for melasma.
• Laser hair removal. Hair follicles contain a reservoir of melanocytes, and that reservoir is the main source of repigmentation when a vitiligo patch recovers, which is why repigmentation often starts as small dots around hairs. Destroying follicles in or near a vitiligo patch removes that reservoir. Many dermatologists therefore advise against laser hair removal over vitiligo patches someone hopes to repigment, in addition to the usual concerns in the piece on laser hair removal.
• Cosmetic tattooing. Microblading, lip blush, and scalp micropigmentation all involve thousands of needle punctures. In active disease, new white patches can appear around tattooed brows or lips, and a tattoo placed over a patch that later repigments will no longer match.
• Friction and pressure. Vitiligo commonly appears where clothing rubs: waistbands, bra straps, watch bands, belt lines. After liposuction or a tummy tuck, weeks of compression garments, fajas, and foam boards create exactly that kind of sustained friction along seams and edges. That does not mean someone with vitiligo should skip compression, which has real functional benefits, but it does argue for well-fitted garments with padded edges and attention to rubbing points, an issue that adds to the general discussion in the piece on waist trainers and fajas after liposuction.
• Adhesives and tape. Tape blisters and stripping injuries are small, but they are injuries. In active disease, gentle adhesives and careful removal are reasonable precautions.

Sun exposure deserves mention too. Depigmented skin has no melanin to protect it and burns easily, and sunburn is itself a recognized Koebner trigger. Healing incisions on a person with vitiligo should be protected from sun with clothing and sunscreen for the same reasons any scar should, with extra urgency. Somewhat counterintuitively, large population studies have not found that vitiligo raises the risk of melanoma or other skin cancers, and some have suggested the opposite, though sunburn remains worth avoiding for every other reason.

What actually repigments skin: creams, light, ruxolitinib, and JAK pills

The short answer: medical treatment can stop vitiligo from spreading and bring back pigment in many patients, most reliably on the face and least reliably on the hands and feet, and since 2022 there has been an FDA-approved repigmentation cream, ruxolitinib, which in its pivotal trials produced at least 75 percent facial improvement in roughly three in ten patients after six months.

The treatments in common use, roughly from mildest to strongest:

• Topical corticosteroids, applied to limited patches, are a long-standing first line. They work, but long-term use on the face thins skin and can trigger rashes such as perioral dermatitis, discussed in the piece on perioral dermatitis and steroid creams. Dermatologists usually use them in pulses or on the body.
• Topical calcineurin inhibitors, tacrolimus ointment and pimecrolimus cream, are used off-label for vitiligo, particularly on the face and eyelids, because they do not thin skin.
• Ruxolitinib cream (sold as Opzelura) was approved by the FDA in July 2022 for nonsegmental vitiligo in patients 12 and older, the first drug approved specifically to repigment vitiligo. In the two phase 3 TRuE-V trials published in the New England Journal of Medicine, about 30 percent of patients reached at least 75 percent improvement in facial depigmentation at 24 weeks, compared with roughly 7 to 11 percent using a placebo cream, and responses continued to improve with longer use. It is applied twice a day to limited body surface areas and, like other JAK inhibitors, carries a boxed warning on its label carried over from the oral drugs, though absorption through the skin is low.
• Narrowband UVB phototherapy, light at around 311 nanometers delivered two or three times a week in a clinic or with a home unit, is the workhorse for widespread disease. It typically takes many months, and the first sign of success is small freckle-like dots of pigment around hair follicles. The excimer laser, at 308 nanometers, delivers similar light to small areas.
• Oral JAK inhibitors such as ritlecitinib and upadacitinib have shown repigmentation in clinical trials for nonsegmental vitiligo and are being studied for approval in that indication. These drugs carry FDA boxed warnings for serious infection, blood clots, major cardiovascular events, and some cancers, warnings that matter before an operation, because surgery itself raises clot and infection risk. Anyone taking one should make sure both the surgeon and the prescribing dermatologist know about the planned operation, as with the biologics and immune-modulating drugs discussed in the piece on hidradenitis suppurativa and surgery.
• Short courses of oral steroids, sometimes given in pulses to halt rapidly spreading disease, are a bridge rather than a long-term plan.

Two patterns hold across nearly every treatment. First, location matters enormously. The face and neck repigment most readily, partly because they have dense hair follicles to supply new melanocytes; the fingers, wrists, lips, and feet, where follicles are sparse, respond poorly. Second, patches with white hairs inside them respond poorly, because the follicular reservoir has been destroyed too. Patients deciding whether to pursue medical treatment or move straight to camouflage should ask specifically about the locations they care about.

Medical treatment also intersects with surgical timing. A topical cream applied to an area near an incision should generally be stopped on the incision until it has healed, and a course of phototherapy may need to pause around an operation. These are details to plan with the dermatologist, not to work out the week before surgery.

Surgery for vitiligo itself: grafting, cell suspension, camouflage, and depigmentation

The short answer: stable vitiligo patches that have not responded to medical treatment can be repigmented surgically by moving melanocytes from normal skin into the white area, either as small grafts or as a suspension of cells, and outcomes are strongest in segmental and localized disease that has been stable for at least a year.

The surgical options for vitiligo fall into two groups.

Tissue grafts move small pieces of pigmented skin into the white patch:

• Punch minigrafting, in which tiny cylinders of skin, often 1 to 2 millimeters across, are taken from a hidden donor site and set into holes in the white patch. Pigment spreads outward from each graft over months, ideally merging. It is simple and inexpensive but can leave a bumpy, cobblestone texture, particularly on the face, so it is used mainly on small patches in less conspicuous places, and a small test graft is often done first.
• Suction blister epidermal grafting, in which suction raises a blister on normal skin and the blister roof, a very thin layer containing melanocytes, is transferred to the prepared patch. It tends to leave little texture change and suits the lips and eyelids, though it is slow.
• Thin split-thickness skin grafts, which cover larger areas faster but carry more risk of visible edges and texture mismatch.

Cell suspension techniques, often called non-cultured epidermal cell suspension or melanocyte keratinocyte transplantation, take a thin shave of normal skin, break it down into individual cells in a laboratory or a point-of-care device, and spread the suspension over a white patch whose surface has been gently abraded with a laser or dermabrasion. A small donor area can treat a recipient area several times larger. In June 2023 the FDA approved one such point-of-care device, the RECELL system, for repigmenting stable vitiligo lesions in adults. Cultured melanocyte techniques, in which cells are grown in a lab over weeks, are mostly confined to specialized centers.

Two caveats run through all surgical repigmentation. Results depend on stability, since grafting into active disease frequently fails, and the donor site is itself an injury that can Koebnerize in the wrong patient, which is why test grafts and a year of stability are standard. And the color match is rarely perfect. Repigmented skin can come back darker or lighter than its surroundings, and most protocols combine surgery with light therapy afterward to help pigment spread.

Medical tattooing of vitiligo, implanting skin-colored pigment into the white patch, is sometimes offered as camouflage. The difficulties are well known: matching skin tone that changes with season and sun, the risk that the tattoo itself triggers new patches in active disease, and the problem that a patch which later repigments will now be the wrong color. The broader limits are covered in the piece on scar camouflage and medical tattooing, and they apply with more force here. Laser removal of a mismatched cosmetic tattoo carries its own risks, discussed in the piece on laser tattoo removal.

Cosmetic camouflage without needles is underused and underrated. Self-tanning products containing dihydroxyacetone stain the outer layer of skin and can make white patches far less conspicuous for days at a time. Specialized high-coverage makeup is waterproof and durable. These options carry no Koebner risk, and the practical advice in the piece on makeup after surgery translates directly.

Depigmentation therapy is the opposite approach, used for people whose vitiligo already covers most of their body. Monobenzone cream, and sometimes lasers, remove the remaining pigment so that the skin is uniformly light. It is permanent, it is a serious decision with real social and psychological consequences, particularly for people with deeper skin tones, and it belongs in the hands of a dermatologist with experience, not a cosmetic clinic.

Vitiligo also changes the visual stakes of ordinary cosmetic procedures on deeper skin. The contrast between a white patch and surrounding skin is larger, a Koebner line along a scar is more visible, and the general pigment concerns raised in the piece on cosmetic procedures on deeper skin tones apply with more weight. The same is true of hand procedures: the backs of the hands and fingers are among the most common sites of vitiligo and among the hardest to repigment, a point worth raising before any of the treatments in the piece on hand rejuvenation.

The honest summary

Vitiligo is an autoimmune disease that destroys pigment cells, and for most people who have it, it is a cosmetic and emotional problem rather than a threat to physical health. It does not, on its own, rule out cosmetic surgery. What it does is add a risk that most patients without vitiligo never face: in a meaningful share of people, especially those whose disease is active, injury to the skin can produce a new white patch exactly where the injury was. Incisions, lasers, peels, microneedling, cosmetic tattooing, tape, sunburn, and garment friction all qualify.

The single most useful fact to establish before any elective procedure is whether the vitiligo is stable, which in practice means no new or growing patches and no white marks at injury sites for about a year. Dated photographs are the most reliable evidence. Active disease is a reason to treat the vitiligo first, with creams such as ruxolitinib or calcineurin inhibitors, light therapy, or, increasingly, JAK inhibitor pills, and to revisit the cosmetic plan once it settles. Anyone taking an oral JAK inhibitor should make sure both the surgeon and the dermatologist are coordinating around the operation, and anyone with vitiligo should know whether their thyroid has been checked, alongside the routine evaluation described in the piece on preoperative testing.

For the white patches themselves, the face responds well to medical treatment, the hands and feet poorly. Surgical repigmentation, from minigrafts to cell suspension, works for stable, localized disease, especially the segmental form, and is a specialized field rather than a cosmetic add-on. Tattooing over vitiligo is a riskier camouflage than it is marketed to be; self-tanner and specialized makeup carry no such risk.

The surgeon's job is to ask, and many do not. A consultation in which nobody mentions the white patches on a patient's hands or around the eyes, nobody asks whether they are spreading, and nobody explains what happens if a white line appears along the incision is a consultation worth repeating somewhere else, as the piece on getting a second consultation argues for any plan that leaves important questions unanswered. Vitiligo is common enough that every plastic surgeon has operated on someone with it. The ones worth trusting are the ones who planned for it.